Early diagnosis is critical in treating Lyme disease. However, nearly one quarter of Lyme disease patients are initially misdiagnosed because currently available serological tests have poor sensitivity and specificity during the early stages of infection. Misdiagnosed patients may go untreated and thus progress to late-stage Lyme disease, where they face longer and more invasive treatments, as well as persistent symptoms.
Existing tests assess the presence of antibodies against bacterial proteins, which take weeks to form after the initial infection and persist after the infection is gone. Now, a nanotechnology-inspired technique developed by researchers at the University of Pennsylvania may lead to diagnostics that can detect the organism itself.
“When you’re initially infected with the Lyme disease bacterium, you don’t develop antibodies for many days to a few weeks,” Johnson said. “Many people see their physician before antibodies develop, leading to negative serological test results. And after an initial infection, you’re still going to have these antibodies, so using these serological diagnostics won’t make it clear if you’re still infected or not after you’ve been treated with antibiotics.”
The research team’s idea was to flip the process around, using laboratory-produced antibodies to detect the presence of proteins from the organism. This is an extension of previous work Johnson’s lab has done connecting other biological structures, such as olfactory receptors and DNA, to carbon nanotube-based devices.
Carbon nanotubes, rolled-up lattices of carbon atoms, are highly conductive and sensitive to electrical charge, making them promising components of nanoscale electronic devices. By attaching different biological structures to the exteriors of the nanotubes, they can function as highly specific biosensors. When the attached structure binds to a molecule, that molecule’s charge can affect the electrical conduction of the nanotube, which can be part of an electrical circuit like a wire. Such a device can therefore provide an electronic read-out of the presence, or even concentration, of a particular molecule.
To get the electrical signal out of these nanotubes, the team first turned them into transistor devices.
“We first grow these nanotubes on what amounts to a large chip using a vapor deposition method, then make electrical connections essentially at random,” Johnson said. “We then break up the chip and test all of the individual nanotube transistors to see which work the best.”
In their recent experiment, Johnson’s team attached antibodies that naturally develop in most animals that are infected with the Lyme disease bacterium to these nanotube transistors. These antibodies naturally bind to an antigen, in this case, a protein in the Lyme bacterium, as part of the body’s immune response.
“We have a chemical process that lets us connect any protein to carbon nanotubes. Nanotubes are very stable, so we have a very reactive compound that binds to the nanotube and also has a carboxylic acid group on the other end. For biochemists, getting any kind of protein to bind to a carboxylic acid group is just child’s play at this point, and we have worked with them to learn how to perform this chemistry on the side wall of nanotubes. “
After using atomic-force microscopy to show that antibodies had indeed bound to the exteriors of their nanotube transistors, the researchers tested them electrically to get a baseline reading. They then put the nanotubes in solutions that contained different concentrations of the target Lyme bacteria protein.
“When we wash away the solution and test the nanotube transistors again, the change in what we measure tells us that how much of the antigen has bound,” Johnson said. “And we see the relationship we expect to see, in that the more antigen there was in the solution, the bigger the change in the signal.”
The smallest concentration the nanotube devices could detect was four nanograms of protein per milliliter of solution.
“This sensitivity is more than sufficient to detect the Lyme disease bacterium in the blood of recently-infected patients and may be sufficient to detect the bacterium in fluids of patients that have received inadequate treatment,” Brisson said.
“We really want the protein we are looking to detect to bind as close to the nanotube as possible, as that is what increases the strength of the electrical signal,” Johnson said. “Developing a smaller, minimal version of the antibody — what we call a single chain variable fragment — would be a next step.
“Based on our previous work with single chain variable fragments of other antibodies, this would probably make such a device about a thousand times more sensitive.”
The researchers suggested that, given the flexibility of their technique for attaching different biological structure, eventual diagnostic tools could incorporate multiple antibodies, each detecting a different protein from the Lyme bacterium. Such a setup would improve accuracy and cut down on the possibility of false-positive diagnoses.
“If we were to do this type of test on a person’s blood now, however, we would say the person has the disease,” Johnson said. “The first thought is that if you detect any protein coming from the Lyme organism in your blood, you are infected and should get treatment right away.”